Medscape

NSCLC Patients Without EGFR Mutations Better on Chemo

For patients with non–small cell lung cancer (NSCLC) that has tested positive for EGFR mutations, treatment with targeted EGFR tyrosine kinase inhibitors (TKIs) such as erlotinib (Tarceva, Osi ...
News Medical

New blood test can accurately, quickly identify genetic mutations linked to NSCLC

Identification of a specific genetic mutation in patients with non-small-cell lung cancer (NSCLC) helps clinicians select the best treatment option. Potential NSCLC patients usually undergo invasive ...
Targeted Oncology

Phase 3 Trial of Calderasib Combo Launched in Advanced KRAS G12C-Mutant NSCLC

The phase 3 KANDLELIT-007 trial (NCT07190248) evaluating the KRAS G12C inhibitor calderasib (MK-1084) plus subcutaneous pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex; SC pembrolizumab) ...
Medscape

Gefitinib Yields Superior Outcomes vs Chemotherapy in EGFR-Mutation-Positive NSCLC

Several reports have noted that individuals with NSCLC whose tumors are documented to contain a mutation in the EGFR receptor have a substantially greater chance of responding to small-molecule ...
News Medical

Zongertinib shows promising efficacy in HER2 mutation-positive NSCLC

The HER2-specific tyrosine kinase inhibitor zongertinib was well tolerated and demonstrated promising efficacy in patients with HER2 mutation-positive non-small cell lung cancer, meeting the primary ...

AstraZeneca's Tagrisso® and Calquence® Among First Oncology Treatments Granted Accelerated Access Through Ontario's FAST Program

CNW/ - AstraZeneca Canada is pleased to announce that Tagrisso® (osimertinib) and Calquence® (acalabrutinib tablets) are now ...
The American Journal of Managed Care

CheckMate 9LA at 6 Years Shows Enduring Benefits From Dual Immunotherapy Plus Chemotherapy in Metastatic NSCLC

CheckMate 9LA showed a 26% overall survival benefit for metastatic NSCLC patients treated with nivolumab and ipilimumab plus ...
MedPage Today

Gregory Masters, MD, on Treating NSCLC With Driver Mutations

A year ago, ASCO released a clinical practice guideline on systemic therapy for patients with stage IV non-small cell lung cancer (NSCLC) without driver alterations. Part two has now been released, ...
Nasdaq

ArriVent BioPharma Reports Promising 16-Month Median Progression-Free Survival for Firmonertinib in First-Line NSCLC Patients with EGFR PACC Mutations

16.0 months median progression-free survival (mPFS) with firmonertinib indicates strong efficacy in first-line patients with EGFR PACC mutant non-small cell lung cancer (NSCLC). Robust central nervous ...
Seeking Alpha

Lunit to Present AI Study on EGFR Mutation Prediction in NSCLC at AACR 2025 in Collaboration with AstraZeneca

AI-powered model predicts EGFR mutations from H&E-stained slides, demonstrating robust performance across diverse clinical settings and helping overcome barriers to molecular testing in NSCLC EGFR ...
Business Insider

TOLREMO therapeutics Receives Two FDA Fast Track Designations for TT125-802 in Pretreated, Advanced or Metastatic NSCLC With Either an EGFR or a KRAS-G12C Mutation

TT125-802 is a small molecule CBP/p300 bromodomain inhibitor that shows clinical activity as single agent in solid tumors, including advanced EGFR-mutated and KRAS-G12C-mutated non-small cell lung ...